Bupivacaine + Sufentanil epidural — Competitive Intelligence Brief

Bupivacaine + Sufentanil epidural (Bupivacaine + Sufentanil epidural) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid combination. Area: Anesthesia and Pain Management.

marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil) Anesthesia and Pain Management Small molecule

Target snapshot

Bupivacaine + Sufentanil epidural (Bupivacaine + Sufentanil epidural) — Charles University, Czech Republic. Bupivacaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that binds to mu receptors to provide analgesia, together delivering epidural anesthesia and pain relief.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine + Sufentanil epidural TARGET	Bupivacaine + Sufentanil epidural	Charles University, Czech Republic	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil)
Levobupivacaine plus sufentanil epidural infusion	Levobupivacaine plus sufentanil epidural infusion	University of Genova	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu-opioid receptor (sufentanil)
Hyperbaric bupivacaine+Sufentanil	Hyperbaric bupivacaine+Sufentanil	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (sufentanil)
Bupivacaine heavy and Morphine	Bupivacaine heavy and Morphine	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (morphine)
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml	Levobupivacaine 0.07% + Sufentanil 0.3µg/ml	Dr Madeleine Wilwerth	phase 3	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)
Levobupivacaine 0.1% + Sufentanil 0.2µg/ml	Levobupivacaine 0.1% + Sufentanil 0.2µg/ml	Dr Madeleine Wilwerth	phase 3	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid combination class)

1. Dr Madeleine Wilwerth · 2 drugs in this class
2. Fundación Pública Andaluza Progreso y Salud · 2 drugs in this class
3. Charles University, Czech Republic · 1 drug in this class
4. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
5. University of Genova · 1 drug in this class